Object. Moyamoya disease/syndrome (MMD/S) is a progressive, occlusive vasculopathy of the intracranial vasculature that leads to ischemic and hemorrhagic strokes. Significant debate exists regarding the role of indirect cerebrovascular bypass surgery in its management. The authors review their institution's experience with indirect bypass in the surgical management of patients with MMD/S.
M oyaMoya syndrome (MMS) is a cerebrovascular condition characterized by progressive stenosis of the intracranial internal carotid arteries (ICAs) and their proximal branches. Compensatory collateral vasculature develops near the carotid apex, cortical surface, leptomeninges, and external carotid artery (ECA) branches supplying the dura and skull base due to a chronic reduction in intracranial blood flow. Classically, MMS is defined as the presence of moyamoya vasculopathy in association with a recognized clinical condition or unilateral moyamoya vasculopathy in the absence of an associated condition. Moyamoya disease (MMD) is defined as idiopathic bilateral intracranial vasculopathy without known associated risk factors. 18 The condition was first described in 1957 by Takeuchi and Shimizu as "hypoplasia of the bilateral internal carotid arteries." 23 The term "moyamoya" was coined in 1969 by Suzuki and Takaku, who reported on 20 cases of a disease "which produces an abnormal net-like blood vessel picture in the base of the brain" with an appearance on angiography "like a puff of cigarette smoke drifting in the air." 22 Moyamoya has been observed in people of various ethnic backgrounds, including American and European populations, although the disease was first considered to affect solely those of Asian heritage. Natural history data
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suggests that the incidence peaks in children at approximately 5 years of age and in adults between 40 and 50 years of age. 10, 18 There are twice as many female patients as male patients. Epidemiological data indicate the prevalence of moyamoya to be 0.086 cases per 100,000 persons in North America, 24 whereas 3 Japanese children are affected for every 100,000 children. 2 Patients afflicted with MMS largely suffer from 3 common disease sequelae: brain ischemia (i.e., seizures, transient ischemia attacks [TIAs] , and stroke), intracranial hemorrhage from fragile moyamoya vessels, and headache. 7 In North American adults, the majority of patients present with symptoms of ischemia as opposed to hemorrhage, and the rate of hemorrhage in adults is roughly 7 times higher than that in children. 9 At present, no reliable medical treatment exists for the primary disease process causing moyamoya vasculopathy. Current therapies are aimed at preventing symptoms and negative disease sequelae by restoring and improving blood flow to affected cerebral hemispheres. Antiplatelet and anticoagulant agents have been used to reduce the risk of ischemic stroke, and calcium channel blockers have been used to treat headache symptoms. 18 Given that moyamoya preferentially affects the ICA system, surgical treatment exploits the ECA as a source to restore blood flow to the affected cerebrum, via either a direct or indirect approach. With direct revascularization, the superficial temporal artery (STA) or occipital artery is directly anastomosed to a cortical artery, such as a branch of the middle cerebral artery (MCA). In adults, direct revascularization via STA-MCA bypass has been demonstrated to reduce the incidence of ischemic events by immediately increasing blood flow to the ischemic brain.
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This procedure can be technically difficult, especially in children with relatively small vessels, and relies on a robust donor and recipient vessel for successful bypass, limiting its application to all affected patients. 18 Indirect revascularization procedures also have been described for MMD/S. One method, encephaloduroarteriosynangiosis (EDAS), is a form of indirect revascularization, in which an ECA branch is directly juxtaposed to the leptomeninges overlying at-risk brain to promote angiogenesis and collateral vessel formation without direct arterial bypass.
14 Unlike direct revascularization procedures, however, augmentation of cerebral blood flow following indirect procedures is delayed by weeks to months. While several studies have demonstrated the utility of the EDAS procedure in patients afflicted with MMD/S, 19, 21 there remains controversy over its clinical benefit. 6, 15 In this study, we report on the clinical outcomes following EDAS in a North American adult cohort and demonstrate the long-term efficacy of this indirect procedure in reducing rates of ischemic events and hemorrhages in patients with moyamoya.
Methods
With approval from the institutional review board at Massachusetts General Hospital, the records of 37 adult patients with imaging-confirmed MMD/S undergoing EDAS by a single surgeon from 1996 to 2013 were reviewed. Patients with both MMD and MMS were included in the analysis. Initially, data in 48 patients with MMD/S were reviewed. Five pediatric patients and 6 adult patients who underwent direct bypass were excluded from our analysis.
Age, sex, ethnicity, antiplatelet and anticoagulant use, hormone therapy use (e.g., oral contraceptives), cigarette smoking status, presentation characteristics, laterality of disease, associated systemic and vascular conditions, Suzuki grade, length of stay (LOS), operative complications, and postoperative course were recorded. The number of neurological events (i.e., seizures, TIAs, strokes, and hemorrhages) sustained and each patient's modified Rankin Scale (mRS) score were recorded pre-and postoperatively for comparison. Of note, TIA was defined as a reversible neurological sign or symptom, whereas stroke was defined as a persistent neurological deficit with radiographic correlation.
Time to surgery was recorded in months as the time from diagnosis of MMD/S to EDAS. The decision to offer surgery, the type of surgery, and the timing of surgery were based on discussions among the patient's providers, specifically the neurologist and neurosurgeon. Patients had at least 1 month of formal postoperative neurosurgical follow-up without routine postoperative imaging such as CT or MR angiography or conventional angiography.
Surgical Technique
All patients underwent an EDAS procedure with an ipsilateral STA donor vessel. The patient was positioned for a frontotemporal craniotomy in the standard fashion. The course of the STA was mapped with a Doppler ultrasonography probe from the zygoma to the superior temporal line (STL) (Fig. 1A) . Under microscopic vision, the skin was incised over the STA and the artery was meticulously dissected from the surrounding tissue and underlying temporalis fascia and muscle. The temporalis was divided in the standard fashion to expose the bone. Bur holes were placed just above the zygoma and at the STL; a small craniotomy was created. The dura and arachnoid were opened and the STA was sutured to the exposed pial interface (Fig. 1B) . The dura was closed over the STA (Fig. 1C) , and the bone flap was replaced with ample space for the vessel (Fig. 1D ). All patients were maintained on an antiplatelet agent perioperatively with strict systolic blood pressure and hydration goals to avoid relative hypotension.
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Statistical Analysis
Analysis was performed using the statistical program R (http://www.r-project.org). Descriptive statistics were performed for demographic data. Preoperative and postoperative mRS scores were analyzed using a marginal homogeneity test. The number of preoperative and postoperative neurological events (i.e., TIAs, strokes, and hemorrhages) was analyzed with nonparametric statistics. A p value of < 0.05 was considered statistically significant. Patient data including preoperative events, postoperative events, and surgeries were visualized in a foreststyle scatterplot.
Results
Demographic data are presented in Table 1 . Thirty patients (81%) of 37 were female and 21 of 37 (57%) had bilateral disease. The median age at the time of surgery was 38 years (range 21-60 years). The majority were Caucasian (n = 29), but African American (n = 3), Hispanic (n = 2), Asian (n = 1), and Native American (n = 2) patients were represented. Eighteen (49%) and 4 (11%) patients were on antiplatelet or anticoagulant therapy, respectively, at the time of surgery. Hormone therapy, such as oral contraceptives, was used by 17% of the women; nearly half of the entire population (n = 15; 41%) were actively smoking cigarettes. Ischemic stroke was the most common presentation (n = 18; 49%) followed by TIA (n = 13; 35%), hemorrhage (n = 5; 13%), and seizure (n = 1; 3%). In terms of associated vascular conditions and disease severity, only 5 (13%) patients had an associated aneurysm, and the mean Suzuki grade was 3.46 (median 3; range 2-5).
The primary outcome measure (i.e., mRS score) demonstrated 21 patients with a score of 0-1 preoperatively and 29 with a score of 0-1 postoperatively ( Table  2) . Using a paired marginal homogeneity test, the improvement was statistically significant at p = 0.002. The number of neurological events (i.e., TIA, ischemic stroke, and hemorrhage) was measured for each patient before and after surgery and per hemisphere when relevant. The mean number of events prior to surgery was 1.7, while the mean number of events postoperatively at time of last known follow-up was 0.14 (p < 0.001). Figure 2 demonstrates the time course of preoperative and postoperative events in relation to the first surgery in each patient who underwent EDAS. Table 3 illustrates operative and postoperative data The patient is positioned for a frontotemporal craniotomy in the standard fashion. The course of the STA is mapped with a Doppler ultrasonography probe from the zygoma to the STL. B: Under microscopic vision, the skin is incised over the STA and the artery is meticulously dissected from the surrounding tissue and underlying temporalis fascia and muscle. The temporalis is divided in the standard fashion to expose the bone. Bur holes are placed just above the zygoma and at the STL; a small craniotomy is created. The dura and arachnoid are opened and the STA is sutured to the exposed pial interface. C: The dura is closed over the STA. D: The bone flap is replaced with ample space for the vessel.
per hemisphere. Fifty-two EDAS procedures were performed in 37 patients from 1996 to 2013. Overall, a wide range of time from diagnosis to surgery (range 0.25-168 months) existed. More recently there was a trend toward shorter time from diagnosis to surgery, coinciding with a greater understanding in the literature of the natural history of the disease process and the safety of bypass procedures in MMD/S. The median length of follow-up was 6 months (mean 32.8 months, range, 1-168 months, excluding 1 patient lost to follow-up and censored); at follow-up, patients were evaluated either by the treating neurosurgeon or neurologist. The median LOS was 3 days and the mean LOS was 4.7 days, although this was partially influenced by 1 patient (LOS 40 days) with unrelated medical complications.
The present population also had a small number of perioperative complications. When analyzed by EDAStreated hemispheres, there was a 12% TIA rate and 6% stroke rate within 1 month of surgery. One patient (2%) who underwent bilateral EDAS had an infection on the right side ( Table 4 ). The majority of these perioperative complications reflected ischemic phenomena related to volume status and blood pressure in the immediate postoperative period. Ultimately, patients recovered from these episodes, and at long-term follow-up only 3 patients (6%) had a new sustained neurological deficit and 1 patient (2%) had an intracranial hemorrhage. Within the limits of our follow-up, there were no known deaths related to either the surgical intervention or natural history.
Finally, associated conditions were studied in our patient population, and outside of the risk factors documented in Table 2 , there were no associated conditions such as anemia, radiation exposure, vasculitis, hereditary phakomatoses, associated vascular disorders, trauma, or a positive family history. One patient had Graves' disease, which has been associated with MMS. 13 Interestingly, there were a number of patients who had headache disorders (32%) or psychiatric conditions (24%) associated with moyamoya.
Discussion
Moyamoya disease and syndrome is a rare clinical disorder in North America, but its incidence appears to be increasing, coinciding with a greater awareness among clinicians. Consistent with prior reports, our population reflects similar demographic characteristics within the North American population. 10, 20 Specifically, the majority of our patients were female and Caucasian, and stroke and TIA were the dominant presentation (in contrast with Asian populations). 10 Our population's postoperative LOS (median 3 days; range 2-40 days) was consistent with that reported in literature following revascularization procedures. 20 Aneurysms associated with MMD/S occurred in a small portion of the entire population (13.5%), and further work will be required to understand the relationship and significance of aneurysms and moyamoya angiopathy. Interestingly, 24% of our patients had some type of major psychiatric condition (i.e., severe depression and suicidality). The association between cognitive/mood disorders and MMD/S has been reported, and our research further confirms the importance of considering routine cognitive testing in the long-term management of patients with MMD/S. 5 On the whole, our current data affirm the clinical characteristics and presentation of MMD/S in North America.
At present, there is a vibrant discussion in the lit- erature regarding the optimal surgical management for MMD/S. In a Japanese adult population of 16 patients, Mizoi et al. posited that direct bypass procedures were the treatment of choice, as indirect bypass did not result in sufficient collateral vessel formation to functionally improve cerebral blood flow. 15 Recently, Gross et al. demonstrated in a North American adult cohort that revascularization via direct bypass (29 patients) significantly reduced the rate of moyamoya events from 11% to 4.5% per hemisphere-years, whereas a similar improvement in event rate and functional status was not observed in patients who underwent indirect procedures (13 patients). 6 On the contrary, Starke et al. reviewed 43 North American adult patients with MMD/S and showed that indirect bypass procedures promoted adequate pial collateral vessel formation to improve overall mRS scores, reduce MMD/S event rates, and increase cerebral blood flow, as demonstrated by SPECT imaging. 21 Finally, Abla et al. reviewed the experience with adult moyamoya at the Barrow Neurological Institute and concluded that indirect bypass improved functional outcomes, although a greater benefit was seen following direct bypass procedures. Likewise, we have shown an improvement in mRS scores from those at the time of surgery to the last follow-up examination in addition to a reduced number of neurological events following indirect surgical intervention. We postulate that patients are often symptomatic at the time of presentation and surgery, leading most frequently to mild disability. At follow-up, symptoms tended to have stabilized or resolved, with the majority of the patients in our series suffering no new neurological deficits. The data from our institutional experience in treating North American adult patients with MMD/S suggest that indirect bypass via the EDAS procedure is a safe and effective surgical option, improving functional outcomes and reducing overall neurological events.
In terms of routine follow-up imaging, Starke et al. 9 reported on a large North American cohort following EDAS and noted increased perfusion on SPECT imaging. The utility of SPECT imaging in demonstrating improved cerebral blood flow following EDAS has also been confirmed by Cho et al. 4 This advancement in neuroradiology is significant, as other groups have demonstrated that augmented cerebral blood flow is difficult to appreciate with conventional angiography following EDAS.
3 Our analysis did not include any significant follow-up intracranial vascular imaging. In part, this was due to our institution's practice of reserving follow-up imaging only for those who develop concerning signs or symptoms for ischemia or hemorrhage. In those patients who did have follow-up imaging, assigning a Matsushima grade was challenging because the majority were followed up with CT or MR angiography as opposed to conventional, catheter-based angiography. Furthermore, Matsushima grading did not appear to be an appropriate measure in the post-EDAS population in whom collateralization on imaging is very difficult to identify and does not necessarily correlate with outcome or perfusion. 3, 16 Research is necessary to ascertain the best method (if any) of imaging follow-up in this population of patients undergoing indirect bypass procedures.
Approximately 6% of our patients had perioperative strokes, a rate consistent with that in prior studies reporting postoperative events following direct and indirect revascularization procedures. In reviewing these cases, most were due to known symptomatic disease, but several were related to postoperative volume status and blood pressure irregularity. In our experience, it has been important to ensure that patients are able to maintain adequate cerebral perfusion given their known intracranial stenoses. We have instituted antiplatelet therapy for all patients and have been permissive with blood pressure goals to ensure adequate perfusion in the perioperative period. Schubert et al. recently demonstrated that patients undergoing direct revascularization procedures have improved outcomes with perioperative antiplatelet agent use. 17 However, regarding the use of antiplatelet therapy in MMD/S, significant differences in practice patterns exist.
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Our study has the limitations inherent in any singleinstitution retrospective case series, including selection bias and limited numbers. Additionally, interpretation of results should be made in the context of our limited available follow-up period. While one cannot assume that patients lost to follow-up have experienced no adverse outcomes in the time interval since their last evaluation, it is likely that they would present again if they were to develop neurological symptoms. This would mirror our institutional experience with the quaternary referral patterns seen in patients with other cerebrovascular diseases treated at our center.
Overall, there is a debate in the literature regarding the most appropriate management of MMD/S in the North American population. The literature supports the use of revascularization procedures to prevent ischemic events in these patients, with national data suggesting an increase in the diagnosis of MMD/S and in the use of TIA (w/in 1 mo) 6 (12) stroke (w/in 1 mo) 3 (6) hemorrhage (w/in 1 mo) 0 (0) wound infection 1 (2) sustained new neurological deficits at follow-up stroke 3 (6) seizure 0 (0) hemorrhage 1 (2) extracranial-intracranial bypass (all forms). 1, 6, 7, [19] [20] [21] The type of extracranial-intracranial bypass, however, that is most effective at preventing future neurological events is unclear. Some authors have suggested that direct bypass is superior to indirect bypass, 6, 12 while others have demonstrated good outcomes with EDAS, an indirect technique, in the adult and pediatric populations. 19, 21 Our report adds to the growing literature that EDAS, a form of indirect bypass, is safe and effective in reducing neurological events and improving functional outcomes (i.e., mRS scores) in patients with moyamoya vasculopathy.
Conclusions
Encephaloduroarteriosynangiosis is an effective revascularization procedure for patients afflicted with MMD/S. Larger, randomized clinical studies with longer follow-up will be critical in further defining the natural history of adult MMD/S and in elucidating the optimal medical and surgical treatments.
